Table 3. Correlation between STAT1-nuclear translocation and SVR.
| Treatment response | Total | SVR | Non-SVR | P-value |
| No. of patients | 79 | 29 | 50 | |
| Age, y | 54.4±11.6 | 49.0±13.6 | 57.5±9.0 | 0.00128 |
| Gender (M/F) | 37/42 | 18/11 | 19/31 | 0.0668 |
| ASL (IU/L) | 58.0±51.5 | 59.3±77.7 | 57.3±27.9 | NS |
| ALT (IU/L) | 69.2±61.7 | 79.5±90.3 | 63.3±36.2 | NS |
| G-GTP (IU/L) | 40.8±25.4 | 36.3±30.0 | 43.4±22.3 | NS |
| WBC (/mm3) | 5,190±1,320 | 5,610±1,410 | 4,940±1,220 | 0.0292 |
| Hb (g/dL) | 14.4±1.2 | 14.6±1.2 | 14.2±1.2 | NS |
| Platelets (×104/mm3) | 17.0±6.5 | 18.9±5.1 | 15.9±7.0 | 0.0472 |
| DM (+/−) | 12/67 | 3/26 | 9/41 | NS |
| VR/Null Responder | 51/28 | 29/0 | 22/28 | 0.00000182 |
| RVR (+/−) | 2/77 | 2/27 | 0/50 | NS |
| EVR (+/−) | 28/51 | 21/8 | 7/43 | 0.000000610 |
| Liver Biopsy | ||||
| F (F1/F2/F3/F4) | 29/25/15/10 | 13/11/4/1 | 13/11/4/1 | NS |
| F (F1+F2/F3+F4) | 54/25 | 24/5 | 30/20 | 0.0649 |
| A (A1/A2/A3) | 28/43/8 | 15/13/1 | 13/30/7 | NS |
| A (A1/A2+A3) | 28/51 | 15/14 | 13/37 | 0.0394 |
| Nuclear-STAT1 (%) | ||||
| Zone 1 | 9.14±8.11 | 6.49±5.68 | 10.6±8.93 | 0.0288 |
| Zone 2 | 3.78±3.94 | 2.51±3.31 | 4.52±4.12 | 0.0280 |
| Zone 3 | 7.41±7.07 | 5.66±6.42 | 8.42±7.30 | 0.0948 |
| Total | 6.57±5.29 | 4.77±4.51 | 7.61±5.46 | 0.0203 |
WBC, white blood cell count; Hb, hemoglobin; DM, diabetes mellitus; US, ultrasound finding; CH, chronic hepatitis; LC, liver cirrhosis; VR, virological responder; RVR, rapid virological responder; EVR, early virological responder; SVR, sustained virological responder; F, Staging of Fibrosis; A, Grading of Activity; nuclear-STAT1, STAT1-nuclear translocation; NS, not significant.